Recent Publication:
On February 23, the FDA announced a new approval pathway designed to support the development of drugs for ultra-rare diseases. Often, treatments for ultra-rare diseases have difficulty meeting the agency’s rigorous approval requirements. The FDA has issued a guidance document for the “Plausible Mechanism Framework,” which will allow drugmakers to bypass certain clinical trial requirements […]
Jacqueline has experience assisting health care providers in regulatory compliance matters, payer reimbursement disputes, facility licensure, and other transactions. She also regularly counsels clients on Medicare and Medicaid reimbursement-related issues, HIPAA compliance, and newly passed legislation. In addition, Jacqueline has experience drafting motions for pending litigation, arbitration, and mediation.
Prior to joining Cozen O'Connor as a summer associate, she was a legal intern at a health care policy nonprofit. There she researched proposed and enacted legislation nationwide and examined distinct legal questions related to individuals' health care rights. Jacqueline also participated in the Safe Harbor and Brooklyn Law Incubator & Policy clinics at Brooklyn Law School. She was additionally a judicial intern for the Honorable Joan A. Madden of the New York State Supreme Court.
Prior to beginning her legal career, Jacqueline worked in the entertainment industry.
Jacqueline earned her bachelor’s degree, magna cum laude, from Binghamton University and her law degree, magna cum laude, from Brooklyn Law School.
News
September 05, 2024
Cozen O’Connor is pleased to announce that the firm’s Corporate Practice has been selected by The American Lawyer as a 2024 Best Corporate Practice of the Year finalist for 2024.
November 01, 2022
We celebrate National Pro Bono Week by sharing the high-impact work of Cozen O’Connor attorneys who have contributed to critical voting rights cases.
Publications
March 02, 2026
On February 23, the FDA announced a new approval pathway designed to support the development of drugs for ultra-rare diseases. Often, treatments for ultra-rare diseases have difficulty meeting the agency’s rigorous approval requirements. The FDA has issued a guidance document for the “Plausible Mechanism Framework,” which will allow drugmakers to bypass certain clinical trial requirements […]
February 17, 2026
The FDA recently shared information regarding its flexible approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). Due to the unique nature of the characteristics of CGT, regulatory flexibility must be adapted in a way that encourages increased innovation while still maintaining the integrity of safety and efficacy.
January 20, 2026
Aselle Kurmanova, Danielle Sapega, and Jackie Glennon discuss the FDA’s latest guidance, which outlines how manufacturers can use relevant and reliable real-world evidence to support medical device regulatory decisions.
July 18, 2025
Throughout the country, state governments have been introducing bills which grant state authorities the ability to closely scrutinize health care transactions – specifically, with an eye toward those involving private equity. In Pennsylvania, the recent closure of the Crozer-Chester Medical Center and the bankruptcy of its parent organization...
July 17, 2025
On July 10, 2025, citing a drive to increase transparency, the Food and Drug Administration (“FDA”) published more than 200 complete response letters (CRLs) previously issued to companies that had submitted new drug applications (NDAs) or biologics license applications (BLAs) to the FDA for new drug or biological products. The FDA issues a CRL when it is rejecting a NDA or BLA on the grounds...
May 13, 2025
On May 1, the federal government brought a False Claims Act (“FCA”) suit against three health insurers, as well as three insurance brokers. The Justice Department’s suit alleges that the insurers paid millions of dollars in kickbacks to brokers in exchange for obtaining enrollments into their Medicare Advantage (“MA”) plans in the form of “marketing,” “co-op,” or “sponsorship” payments...
October 28, 2024
In October 2024, Blue Cross Blue Shield (“BCBS”) agreed to a $2.8 billion settlement to resolve allegations of anti-competitive practices in the health insurance market – it is reported to be the largest settlement in a health care antitrust case to date. This landmark case has drawn significant attention from policymakers...
August 19, 2024
California is looking to take the lead on regulating private equity deals in the health care space by introducing bill AB 3129, which requires private equity groups or hedge funds to receive the state attorney general’s approval before purchasing a health care entity. At present, California’s proposal is the most extensive state legislation that seeks to regulate...
July 10, 2024
Under the No Surprises Act, “open negotiation” is the period of time during which payers must disclose to providers important information regarding the claim at issue. On June 14, 2024, CMS announced a 120-calendar-day exception period...
May 15, 2024
Last week, the United States Department of Justice’s Antitrust Division announced the formation of the Task Force on Health Care Monopolies and Collusion (“HCMC”)...
May 08, 2024
On April 23, 2024, the Federal Trade Commission (“FTC”) issued its final rule regarding noncompete clauses, and which determined that such clauses are an unfair method of competition and therefore violate section 5 of the Federal Trade Commission Act (“FTC Act”)...
January 24, 2024
Last week CMS issued its final rule "CMS Interoperability and Prior Authorization" (CMS-0057-F), unchanged from its proposed rule in 2022, which addresses prior authorizations. Prior authorization, a "utilization management" technique, requires a health insurer to consent to a doctor’s proposed...
November 28, 2023
Last month, a cyberattack forced two New York hospitals to divert and even discharge some patients to other facilities, while the affected hospitals shut down their IT systems to address the issue and restore their secure network. [cite] In the wake of this event, New York Governor Kathy Hochul has...
September 22, 2023
On Friday, September 15th, the United States Attorney’s Office for the District of Massachusetts (United States) and the Massachusetts Attorney General’s Office (Massachusetts) filed a joint complaint in the United States District Court for the District of Massachusetts against a...
July 13, 2023
Prior authorizations, one of health insurers’ many “utilization management” techniques, is a hot topic amongst practicing physicians, patients, and regulators, to name a few. The prior-authorization process requires a health insurer to consent to a doctor's proposed course of treatment for a...
July 10, 2023
On Friday, July 7, 2023, the Centers for Medicare & Medicaid Services (CMS) published their long-awaited proposed remedy to the unlawful 340B drug payment reductions.
Background: In 2018, CMS significantly reduced the Average Sales Price (ASP) plus six-percent (6%) formula for calculating...
April 13, 2023
Jacqueline Green authored an article examining the drawbacks of the prior authorization process used by insurance companies.
August 10, 2022
Jacqueline Green authored an article in Law 360 in which she discusses the recently introduced Cannabis Administration and Opportunity Act.
Events & Seminars
Past Events
December 04, 2025
- Philadelphia, PA
December 05, 2023
- Philadelphia, PA